Skip to content

Haemonetics HAE Other, net

Other, net at other companies

Boston Scientific logo
Boston ScientificBSX
$3M+130%
LivaNova logo
LivaNovaLIVN
$1.69M+3,780%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
-$69M+9.2%
Medtronic logo
MedtronicMDT
Danaher logo
DanaherDHR
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's other, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's other, net?
Haemonetics (HAE) reported other, net of -$13K in Q1 2026.
How has Haemonetics's other, net changed year-over-year?
Haemonetics's other, net increased by 51.9% year-over-year, from -$27K to -$13K.
What is the long-term trend for Haemonetics's other, net?
Over 3 years (2023 to 2026), Haemonetics's other, net has grown at a 32.3% compound annual growth rate (CAGR), from -$44K to -$102K.
What does other, net mean?
Includes miscellaneous cash flows related to financing activities that are not categorized as debt issuance, dividends, or share repurchases. This may include changes in non-controlling interests, debt issuance costs, or other unique financing-related transactions. It provides a comprehensive view of non-standard financing cash movements.